-
EP4225790
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4225790
| EP4225790 - ADJUVANT DURVALUMAB IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF CANCER [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 14.07.2023 Database last updated on 16.11.2024 | |
| Former | The international publication has been made Status updated on 22.04.2022 | ||
| Former | unknown Status updated on 28.10.2021 | Most recent event Tooltip | 13.09.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Astrazeneca AB 151 85 Södertälje / SE | [2023/33] | Inventor(s) | 01 /
DENNIS, Phillip Wilmington, Delaware 19850-5437 / US | 02 /
POOLE, Lynne Cambridge Cambridgeshire CB2 0AA / GB | 03 /
MAY, Rena Wilmington, Delaware 19850-5437 / US | [2023/33] | Representative(s) | MacLean, Martin Robert Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB | [2023/33] | Application number, filing date | 21790440.8 | 11.10.2021 | [2023/33] | WO2021EP78050 | Priority number, date | US202063090441P | 12.10.2020 Original published format: US 202063090441 P | [2023/33] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022078958 | Date: | 21.04.2022 | Language: | EN | [2022/16] | Type: | A1 Application with search report | No.: | EP4225790 | Date: | 16.08.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 21.04.2022 takes the place of the publication of the European patent application. | [2023/33] | Search report(s) | International search report - published on: | EP | 21.04.2022 | Classification | IPC: | C07K16/28, A61K39/395, A61K31/00, A61P35/00 | [2023/33] | CPC: |
C07K16/2827 (EP,IL,KR);
C07K16/2818 (US);
A61K31/337 (EP,IL,KR,US);
A61K31/519 (EP,IL,KR,US);
A61K31/555 (EP,IL,KR,US);
A61K33/243 (EP,IL,KR,US);
A61K39/39558 (EP,IL,KR);
A61P35/00 (EP,IL,KR);
A61K2039/505 (US);
A61K2039/507 (EP,IL,KR);
A61K2300/00 (IL,KR);
C07K2317/732 (KR);
C07K2317/76 (EP,IL,KR,US)
(-)
| C-Set: |
A61K39/39558, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/33] | Extension states | BA | 28.03.2023 | ME | 28.03.2023 | Validation states | MA | 28.03.2023 | TN | 28.03.2023 | Title | German: | ADJUVANS DURVALUMAB IN KOMBINATION MIT CHEMOTHERAPIE ZUR BEHANDLUNG VON KREBS | [2023/33] | English: | ADJUVANT DURVALUMAB IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF CANCER | [2023/33] | French: | ADJUVANT DURVALUMAB POUR TRAITER LE CANCER EN COMBINAISON AVEC UNE CHIMIOTHÉRAPIE | [2023/33] | Entry into regional phase | 28.03.2023 | National basic fee paid | 28.03.2023 | Designation fee(s) paid | 28.03.2023 | Examination fee paid | Examination procedure | 28.03.2023 | Examination requested [2023/33] | 28.03.2023 | Date on which the examining division has become responsible | 24.11.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 13.09.2023 | Renewal fee patent year 03 | 12.09.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | by applicant | US9493565 |